A search for solutions as sub-variants of Omicron BA.4, BA.5 found to evade antibodies
According to new data from researchers at Beth Israel Deaconess Medical Center, Harvard Medical, Omicron BA.4 and BA.5 subvariants appear to evade antibody responses in people who have previously been infected with Covid-19 and in those who have been fully vaccinated and boosted. School.
However, vaccination against Covid-19 should still provide substantial protection against serious disease, and vaccine makers are working on updated vaccines that could trigger a stronger immune response against the variants.
The levels of neutralizing antibodies that infection or previous vaccinations cause are several times lower against the BA.4 and BA.5 subvariants compared to the original coronavirus, according to new research published in the New England Journal on Wednesday. of Medicine.
“We observed 3-fold reductions in vaccination and infection-induced neutralizing antibody titers against BA4 and BA5 compared to BA1 and BA2, which are already significantly lower than the original COVID-19 variants,” said said Dr. Dan Barouch, author of the article. and director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, wrote in an email to CNN.
“Our data suggest that these new Omicron subvariants are likely to lead to outbreaks of infections in populations with high levels of vaccine immunity as well as natural BA1 and BA2 immunity,” Barouch wrote. “However, it is likely that vaccine immunity will still provide substantial protection against severe disease with BA4 and BA5.”
The newly published findings echo separate research conducted by scientists at Columbia University.
They recently found that the BA.4 and BA.5 viruses were more likely to evade antibodies from the blood of fully vaccinated and boosted adults compared to other Omicron subvariants, increasing the risk of Covid-19 infections. 19 revolutionaries.
The authors of the separate study say their results indicate a higher risk of reinfection, even in people who already have some immunity to the virus. The U.S. Centers for Disease Control and Prevention estimates that 94.7% of the U.S. population ages 16 and older have antibodies to the coronavirus that causes Covid-19 through vaccination, infection, or both.
BA.4 and BA.5 caused about 35% of new Covid-19 infections in the United States last week, up from 29% the previous week, according to data shared Tuesday by the United States Centers for Disease Control and Prevention. United.
BA.4 and BA.5 are the fastest-spreading variants reported to date, and they are expected to dominate Covid-19 transmission in the US, UK and rest of Europe over the next few months. coming weeks, according to the European Research Centre. Disease prevention and control.
In the New England Journal of Medicine article, among 27 research participants who had been vaccinated and boosted with the Pfizer/BioNTech coronavirus vaccine, researchers found that two weeks after the booster dose, levels of neutralizing antibodies against Omicron subvariants were much lower than response against the original coronavirus.
Levels of neutralizing antibodies were 6.4-fold lower against BA.1; by a factor of 7 against BA.2; by a factor of 14.1 against BA.2.12.1 and by a factor of 21 against BA.4 or BA.5, the researchers described.
Among 27 participants who had previously been infected with the BA.1 or BA.2 subvariants a median of 29 days earlier, the researchers found similar results.
In those who had already been infected – most of whom had also been vaccinated – the researchers described 6.4-fold lower levels of neutralizing antibodies against BA.1; by a factor of 5.8 against BA.2; by a factor of 9.6 compared to BA.2.12.1 and by a factor of 18.7 compared to BA.4 or BA.5.
Further research is needed to determine what exactly neutralizing antibody levels mean for vaccine effectiveness and whether similar findings would emerge among a larger group of participants.
“Our data suggests that COVID-19 still has the ability to mutate further, leading to increased transmissibility and increased antibody leakage,” Barouch wrote in the email. “As pandemic restrictions are lifted, it is important that we remain vigilant and continue to investigate new variants and subvariants as they emerge.”
A separate study, published in the journal Nature last week, found that Omicron can develop mutations to evade immunity elicited by previous BA.1 infection, suggesting that BA-based vaccine boosters. 1 may not provide broad-spectrum protection against newer Omicron subvariants like BA.4 and BA.5.
As for what all of this means in the real world, Dr. Wesley Long, an experimental pathologist at Houston Methodist Hospital, told CNN that people should be aware that they could get sick again, even if they already have had Covid-19.
“I think I’m a bit concerned for people who may have had a false sense of security about it recently with the increase in BA.4 and BA.5, because we’ve seen cases of re-infection and I’m I’ve seen a few cases of re-infection with people who had a BA.2 variant over the past few months,” he said.
Some vaccine manufacturers have developed variant-specific vaccines to improve antibody responses against coronavirus variants and subvariants of concern.
“Reinfections are going to be pretty inevitable until we have vaccines or widespread mandates that will prevent cases from rising again. But the good news is that we are, I think, in a much better situation than we were without the vaccines,” said Pavitra Roychoudhury, acting professor in the Department of Laboratory Medicine and Pathology at the University of Washington, who did not participate in the study. Article from the New England Journal of Medicine.
“There’s so much of this virus out there that it seems inevitable,” she said of Covid-19 infections. “Hopefully the safeguards we have in place will lead to mostly mild infection.”
Moderna’s bivalent Covid-19 vaccine recall, named mRNA-1273.214, elicited a “potent” immune response against the Omicron BA.4 and BA.5 subvariants, the company said Wednesday.
This bivalent booster vaccine candidate contains components of Moderna’s original Covid-19 vaccine and a vaccine that targets the Omicron variant. The company said it is working to complete regulatory submissions in the coming weeks asking to update the composition of its booster vaccine to be mRNA-1273.214.
“As SARS-CoV-2 continues to evolve, we are very encouraged that mRNA-1273.214, our lead knockdown candidate, showed high neutralizing titers against BA subvariants. 4 and BA.5, which represent an emerging global public health threat,” said Stéphane Bancel, chief executive of Moderna, in Wednesday’s announcement. SARS-CoV-2 is the coronavirus that causes Covid-19.
“We will submit this data to regulators urgently and prepare to deliver our next-generation bivalent booster beginning in August, ahead of a potential increase in SARS-CoV-2 infections due to Omicron subvariants in early fall,” Bancel said.
The U.S. Food and Drug Administration’s Vaccines and Related Biologicals Advisory Committee is meeting next week to discuss the composition of Covid-19 vaccines that could be used as boosters this fall.
Data Moderna released on Wednesday, which has not been published in a peer-reviewed journal, showed that a month after a 50-microgram dose of the mRNA-1273.214 vaccine was given to people who had been vaccinated and boosted, the vaccine elicited “potent” neutralizing antibody responses against BA.4 and BA.5, increasing levels 5.4-fold in all participants, whether or not they had previous infection with Covid-19 and 6.3 times in the subset of those with no history of previous infection. These neutralizing antibody levels were about 3 times lower than previously reported neutralizing levels against BA.1, Moderna said.
These results add to data previously published by Moderna earlier this month showing that the 50 microgram dose of the bivalent booster generated a stronger antibody response against Omicron than the original Moderna vaccine.
Data from Moderna suggests that “bivalent booster may confer greater protection against BA.4 and BA.5 omicron strains than re-administration of the original vaccine to increase protection in the population. Although the information is based on antibody levels, the companies comment that similar levels of antibodies protected against clinical disease caused by other strains is the first suggestion of an emerging ‘immune correlate’ of protection, although it is hoped that this ongoing study will also assess clinical disease rates as well as antibody responses,” said Penny Ward, an independent pharmaceutical physician and visiting professor of pharmaceutical medicine at King’s College London, in a statement released Wednesday. by the UK-based Science Media Center. She was not involved in Moderna’s work.
“The bivalent vaccine has been previously reported to be well tolerated with similar temporary ‘reactogenic’ effects to those following the univalent booster injection, so we can anticipate that this new mixed vaccine should be well tolerated,” Ward said. in part. “As we head into the fall with omicron variants dominating the landscape of covid infections, it certainly makes sense to consider the use of this new bivalent vaccine, if it becomes available.”